Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 11—November 2024
Research

Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022

Dongwon Yoon1, Kyungyeon Jung1, Ju Hwan Kim, Hwa Yeon Ko, Byeol-A Yoon2, Ju-Young Shin2Comments to Author , and CoVaSC Investigators
Author affiliation: Sungkyunkwan University Department of Biohealth Regulatory Science, Suwon, South Korea (D. Yoon, K. Jung, J.H. Kim, J.-Y. Shin); Sungkyunkwan University School of Pharmacy, Suwon (D. Yoon, J.H. Kim, H.Y. Ko, J.-Y. Shin); Dong-A University College of Medicine Department of Neurology, Busan, South Korea (B.-A. Yoon); Sungkyunkwan University Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, South Korea (J.-Y. Shin)

Main Article

Table 1

Baseline characteristics stratified by exposure windows in a study of risk for facial palsy after COVID-19 vaccination, South Korea, 2021–2022*

Baseline characteristics Risk window, n = 5,211 Control window, n = 10,531 p value
Mean age, y (SD)
 53.1 (15.9)
 52.8 (16.0)
 0.3147
Age group, y 0.1587
18–29 506 (9.7) 1,005 (9.5)
30–39 597 (11.5) 1,310 (12.4)
40–49 990 (19.0) 1,955 (18.6)
50–59 1,204 (23.1) 2,472 (23.5)
60–69 1,099 (21.1) 2,176 (20.7)
70–79 599 (11.5) 1,113 (10.6)
>80
 216 (4.1)
 500 (4.7)
Sex 0.0417
M 2,849 (54.7) 5,938 (56.4)
F
 2,362 (45.3)
 4,593 (43.6)
Health insurance type 0.4262
National health insurance 5,045 (96.8) 10,170 (96.6)
Medical aid
 166 (3.2)
 361 (3.4)
Region of residence 0.7853
Metropolitan 3,485 (66.9) 7,020 (66.7)
Rural
 1,726 (33.1)
 3,511 (33.3)
Mean CCI (SD)
 1.3 (1.8)
 1.3 (1.7)
 0.0540
CCI group 0.1488
CCI <5 4,866 (93.4) 9,896 (94.0)
CCI <5
 345 (6.6)
 635 (6.0)
Underlying conditions
Myocardial infarction 41 (0.8) 115 (1.1) 0.0689
CHF 164 (3.1) 383 (3.6) 0.1144
Peripheral vascular disease 620 (11.9) 1,139 (10.8) 0.0424
Cerebrovascular disease 315 (6.0) 696 (6.6) 0.1742
Dementia 198 (3.8) 366 (3.5) 0.3031
CPD 676 (13.0) 1,408 (13.4) 0.4886
Rheumatic disease 137 (2.6) 301 (2.9) 0.4107
Peptic ulcer 848 (16.3) 1,634 (15.5) 0.2199
Mild liver disease 1,105 (21.2) 2,179 (20.7) 0.4553
Diabetes mellitus 1,190 (22.8) 2,236 (21.2) 0.0217
Diabetic complications 337 (6.5) 665 (6.3) 0.0289
Hemiplegia or paraplegia 20 (0.4) 56 (0.5) 0.2076
Renal disease 110 (2.1) 222 (2.1) 0.9906
Cancer 258 (5.0) 455 (4.3) 0.0734
Serious liver disease 15 (0.3) 21 (0.2) 0.2743
Solid metastatic tumor 22 (0.4) 32 (0.3) 0.2322
HIV infection 1 (0.0) 6 (0.1) 0.2900

*Values are no. (%) except as indicated. CCI, Charlson Comorbidity Index score; CHF, congestive heart failure; CPD, chronic pulmonary disease.

Main Article

1These first authors contributed equally to this article.

2These last authors contributed equally to this article.

Page created: August 28, 2024
Page updated: October 22, 2024
Page reviewed: October 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external